Glenmark Pharmaceuticals saw its stock price rise by 4% after Ichnos Glenmark Innovation (IGI) announced promising Phase 1 clinical trial results for ISB 2001, a trispecific antibody designed to treat multiple myeloma.
The trial showed an impressive 83% overall response rate (ORR) in heavily pretreated patients at active doses, along with a favorable safety profile.
Glenmark Pharmaceuticals shares opened at ₹1,535.00, reaching a high of ₹1,576.50 and a low of ₹1,521.00 today. The stock’s 52-week high is ₹1,830.95, while its 52-week low stands at ₹771.00.
As of 9:33 am, Glenmark shares were trading 3.35% higher at Rs 1,564.90 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
